VJHemOnc

The Video Journal of Hematology & Hematological Oncology is dedicated to providing up-to-date information & international expertise

[VJHemOnc @VJHemOnc]

Want to hear about the evidence-based consensus treatment recommendations for R/R IDH1-mutated acute myeloid #leukemia? 🩸

@jorgecortesmd of @ONealCancerUAB shares his insights in an exclusive interview from #EHA2026:

🎥 👉 https://t.co/6YQdwTy3SK

#AMLsm #Leusm #HemOnc @EHA_Hematology

[VJHemOnc @VJHemOnc]

At #EHA2026, @MariaTeresaVoso (@unitorvergata) presented findings from the final analysis of the APOLLO trial evaluating ATRA-ATO versus AIDA in high-risk acute promyelocytic #leukemia.

To find out more, click here:
👉 https://t.co/KXM8AUtvrP 👈

#Leusm #TrialUpdate #HemOnc

[VJHemOnc @VJHemOnc]

Why have BTK inhibitors not had the same impact in #FollicularLymphoma as in other B-cell malignancies?🤔

In a recent interview at #EHA2026, we spoke with @DanilovLab of @cityofhope, who shared insight into this - click here to watch:

🎥 👉 https://t.co/11TZw2EEYn

#LYMsm #NonHodgkinLymphoma #HemOnc

[VJHemOnc @VJHemOnc]

#EHA2026 | @mpdrc of @LevineCancer shares outcomes from the SURPASS-ET trial assessing early versus delayed initiation of ropeginterferon alfa-2b in high-risk essential thrombocythemia:

➡️ https://t.co/hYMLGTL1Bb.

#TrialUpdate #CTSM #MPNsm @EHA_Hematology

[VJHemOnc @VJHemOnc]

Don't forget to check out our top updates from #EHA2026 🚨🎥
Watch our exclusive video interviews to learn more:

🩸Findings from MonumenTAL-3: Tal+Dara±Pom versus Dara+Pom+Dex in R/R #MultipleMyeloma - Peter Voorhees (@PlasmaCellPete): https://t.co/dJfOOjF4gM

🩸The Phase III SENTRY trial: selinexor plus ruxolitinib in JAK inhibitor-naïve #myelofibrosis - Claire Harrison (@harrisoncn1): https://t.co/6yHopOpXKr

🩸Results from the Phase III FRONTMIND study: tafasitamab, lenalidomide, and R-CHOP in frontline #DLBCL - Umberto Vitolo: https://t.co/VcOfl3MguK

🩸Long-term results from KOMET-007: ziftomenib with 7+3 in newly diagnosed NPM1-m or KMT2A-r AML - Amer Zeidan (@Dr_AmerZeidan): https://t.co/8dU7ILW4eS

🩸BRUIN CLL-322 trial update: fixed-duration pirtobrutinib plus VR in previously treated CLL - Matthew Davids (@DrMDavids): https://t.co/T58PjFNBLU

#MMSM #Leusm #LYMsm #AMLsm #CLLsm #MPNsm #TrialUpdate #CTSM #ImmunOnc #HemOnc @EHA_Hematology

[VJHemOnc @VJHemOnc]

It was lovely to speak with @heMEGirl_MD (@TGHCares) at #EHA2026, who shared advice for community oncologists referring patients with #Lymphoma for #CARTCell therapy. 🩸

Click here to watch:
🎥 ➡️ https://t.co/wykuzGQQe6

#LYMsm #HemOnc #ImmunoOnc

[VJHemOnc @VJHemOnc]

Want to find out about the hottest updates in MPNs from #EHA2026?🚨📣

Then click here to watch our interview with @bose_prithviraj of @UTMDAnderson, who shared his expert insights:

👉 https://t.co/tE0ewBHCm9 👈

#MPNsm #ImmunoOnc #HemOnc @EHA_Hematology

[VJHemOnc @VJHemOnc]

Earlier this month we attended #ASCO26 to catch up with #HemOnc experts and hear updates in #Myeloma, #Lymphoma, & more!🩸

If you haven't already, make sure to explore our expert video interviews from the event here:

🎥 👉 https://t.co/RUlE6Jkg4q

#CTSM #MMSM #Leusm #LYMsm #MPNsm

[VJHemOnc @VJHemOnc]

At #EHA2026, we spoke with the lovely Uma Borate (@beatalleukemia, @OSUCCC_James), who presented results from the OPTI-AML trial comparing 28- versus 14-day venetoclax in patients with newly diagnosed acute myeloid #leukemia aged 60+.🩸

Watch the full interview here:
🎥 https://t.co/NMSvTQcN4c

#AMLsm #Leusm #TrialUpdate #HemOnc

[VJHemOnc @VJHemOnc]

It's always a pleasure to speak with the wonderful @KerryARogersMD about all things CLL!🩸

At #EHA2026, Dr Rogers discussed long-term follow-up data from a Phase II study evaluating venetoclax added to ibrutinib in patients with CLL who developed BTKi resistance mutations:

🎥 ➡️ https://t.co/fIvM11dbhm

#CLLsm #Leusm #Leukemia #CTSM #TrialUpdate #HemOnc

[VJHemOnc @VJHemOnc]

Key insights from our newest CLL Session - Part 1 🎥 🔎

Watch this fantastic discussion on the role of BTK inhibitors in CLL, featuring leading experts @DrMDavids, @tobyeyre82, & Jennifer Woyach.🩸

Click here:
➡️ https://t.co/zoRZ2giDWn

#CLLsm #Leusm #Leukemia #HemOnc

[VJHemOnc @VJHemOnc]

LAST CHANCE to register for our Post-EHA 2026 #AML Highlights, taking place TOMORROW 🩸

Webinar series by VJHemOnc featuring presentations & discussions on selected abstracts from the 31st Congress of the European Hematology Association (EHA) 💻

📍 Webinar series
🗓️ 25 June

🎙️ Chair: @Daver_Leukemia | Moderators: @DrEmmaSearle & @EuniceWangMD

View the agenda and REGISTER 🔗 👉 https://t.co/AsfOyTv4YF

Also covering:
📌 #MPNs - Chaired by: Claire Harrison
📌 #Lymphoma - Chaired by: Krish Patel
📌 #MDS - Chaired by: Amer Zeidan
📌 #Myeloma - Chaired by: Karthik Ramasamy
📌 #CLL - Chaired by: Alexey Danilov

[VJHemOnc @VJHemOnc]

Thank you to @OcioEnrique of @HUnivValdecilla for stopping by at #EHA2026 to share insight into the final analysis of the DREAMM-9 trial evaluating Bela-VRd in transplant-ineligible patients with newly diagnosed #MultipleMyeloma.

Click here to watch:
👉 https://t.co/2HPI5xtl0h 👈

#MMSM #Myeloma #HemOnc #ImmunoOnc #CTSM #TrialUpdate

[VJHemOnc @VJHemOnc]

LAST CHANCE to register for our Post-EHA #MPN 2026 Highlights, taking place TOMORROW 🩸

Webinar series by VJHemOnc featuring presentations & discussions on selected abstracts from the 31st Congress of the European Hematology Association (EHA) 💻

📍 Webinar series
🗓️ 24 June

🎙️ Chair: @harrisoncn1 | Moderators: John Mascarenhas & @jjkiladjian

View the agenda and REGISTER 🔗 👉 https://t.co/nXMPgBc94S

Also covering:
📌 #Lymphoma - Chaired by: @KrishPatelMD
📌 #AML - Chaired by: @Daver_Leukemia
📌 #Myeloma - Chaired by: Dr Karthik Ramasamy
📌 #MDS - Chaired by: @Dr_AmerZeidan
📌 #CLL - Chaired by: Dr Alexey Danilov

[VJHemOnc @VJHemOnc]

Is autologous transplant still needed in relapsed #HodgkinLymphoma? 🤔🩸

Cathy Burton shared insight into this at #EHA2026, reviewing emerging evidence suggesting that selected patients may not require a consolidative transplant.

Watch the interview here:
🎥 👉 https://t.co/8gXP31DIfU

#LYMsm #Lymphoma #HemOnc

[VJHemOnc @VJHemOnc]

Couldn't make it to #EHA2026? We've got you covered!😄

Catch up on the hottest news and updates in #HemOnc and #Hematology with our exclusive expert video interviews from the event!🎥🩸

Explore now:
➡️ https://t.co/bQTd6eqUIu ⬅️

#MMSM #LYMsm #Leusm #MPNsm #MDSsm #AMLsm #CLLsm #ALLsm #ImmunoOnc @EHA_Hematology

[VJHemOnc @VJHemOnc]

LAST CHANCE to register for our Post-EHA 2026 #Lymphoma Highlights, taking place TOMORROW 🩸

Webinar series by VJHemOnc featuring presentations & discussions on selected abstracts from the 31st Congress of the European Hematology Association (EHA) 💻

📍 Webinar series
🗓️ 23 June

🎙️ Chair: @KrishPatelMD | Moderators: Joanna Rhodes & @tobyeyre82

View the agenda and REGISTER 🔗 👉 https://t.co/fo01c2ZHfY

Also covering:
📌 #MPNs - Chaired by: Claire Harrison
📌 MDS - Chaired by: Amer Zeidan
📌 #AML - Chaired by: Dr Naval Daver
📌 #Myeloma - Chaired by: Dr Karthik Ramasamy
📌 #CLL - Chaired by: Alexey Danilov

[VJHemOnc @VJHemOnc]

The ASC4FIRST trial evaluated asciminib in patients with newly diagnosed chronic phase CML.🩸

In an interview at #EHA2026, Timothy Hughes of @sahmriAU shared findings from the week 144 analysis of this trial.🎥

Watch here:
👉 https://t.co/mvbAOLmMZy

#CMLsm #Leusm #Leukemia #HemOnc

[VJHemOnc @VJHemOnc]

Type II JAK2 inhibitors are an exciting potential therapeutic strategy for #Myelofibrosis.🩸

At #EHA2026, we caught up with John Mascarenhas (@IcahnMountSinai), who shared initial findings from the first-in-human trial investigating AJ1-11095 in pts with MF previously treated with a Type I JAK2 inhibitor.

Watch the interview here:
👉 https://t.co/n3qNwkRG4e

#MPNsm #CTSM #TrialUpdate #HemOnc

[VJHemOnc @VJHemOnc]

In a recent interview, @LuskinMarlise of @DanaFarber shared findings from a Phase II study evaluating venetoclax plus mini-hyper-CVD in older adults with newly diagnosed Philadelphia chromosome-negative ALL.

Click here to watch:
🎥 https://t.co/3GA6PG5xiA

#ALLsm #Leusm #Leukemia #HemOnc #CTSM #TrialUpdate